Genocea to Host Fourth Quarter 2020 Corporate Update Conference Call & Webcast

Rhea-AI Summary

Genocea Biosciences (NASDAQ: GNCA) will announce its fourth quarter 2020 financial results and provide a corporate update on February 11, 2021, at 8:30 a.m. ET. Participants can join the call by dialing (844) 826-0619 for domestic or (315) 625-6883 for international access, using conference ID 5767897. Additionally, the event will be available via a live audio webcast on Genocea's investor relations page. A replay will be accessible on the website shortly after the call for 90 days. Genocea focuses on innovative cancer immunotherapies using its ATLAS™ platform.

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2020 financial results and corporate update conference call and live audio webcast on Thursday, February 11th at 8:30 a.m. ET.

Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 5767897. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. 

A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.

About Genocea Biosciences, Inc.

Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood. To learn more, please visit https://www.genocea.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.

Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com

 

FAQ

When will Genocea Biosciences release its fourth quarter 2020 financial results?

Genocea Biosciences will release its fourth quarter 2020 financial results on February 11, 2021, at 8:30 a.m. ET.

How can I access Genocea Biosciences' conference call?

You can access the conference call by dialing (844) 826-0619 for domestic calls or (315) 625-6883 for international calls, using conference ID 5767897.

Where can I find the live audio webcast for Genocea's corporate update?

The live audio webcast for Genocea's corporate update will be available on their investor relations page at https://ir.genocea.com/events-presentations.

Will there be a replay of Genocea's fourth quarter financial results call?

Yes, a replay of the call will be available approximately two hours after the event and will be archived for 90 days.

What is the focus of Genocea Biosciences' research?

Genocea Biosciences focuses on developing personalized cancer immunotherapies through their ATLAS™ platform.